Literature DB >> 12848736

The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.

P J Turner1, J M Greenhalgh.   

Abstract

In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated from serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. lwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12848736     DOI： 10.1046/j.1469-0691.2003.00591.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  9 in total

1.  Resistance of gram-negative non-fermentative bacilli causing bloodstream infection, Vienna, 1996-2003.

Authors:  F Daxboeck; O Assadian; A Blacky; W Koller; A M Hirschl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

Review 2.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

5.  Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002-2006.

Authors:  M Wadl; K Heckenbach; I Noll; S Ziesing; W Pfister; J Beer; S Schubert; T Eckmanns
Journal:  Infection       Date:  2010-01-27       Impact factor: 3.553

6.  Meropenem Resistance among Acinetobacter Positive Clinical Samples in a Tertiary Care Centre in Nepal: A Descriptive Cross-sectional Study.

Authors:  Nisha Sharma; Bibechan Thapa; Ashirbad Acharya; Bijendra Raj Raghubanshi
Journal:  JNMA J Nepal Med Assoc       Date:  2021-09-11       Impact factor: 0.556

Review 7.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

8.  Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience.

Authors:  Thabit Alotaibi; Abdulrhman Abuhaimed; Mohammed Alshahrani; Ahmed Albdelhady; Yousef Almubarak; Osama Almasari
Journal:  SAGE Open Med       Date:  2021-03-15

9.  In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy.

Authors:  Maria Lina Mezzatesta; Giusi Trovato; Floriana Gona; Vito Mar Nicolosi; Daria Nicolosi; Alessandra Carattoli; Giovanni Fadda; Giuseppe Nicoletti; Stefania Stefani
Journal:  Ann Clin Microbiol Antimicrob       Date:  2008-02-08       Impact factor: 3.944
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.